Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2022
Has there actually been early resolution for early resolution resubmissions?
15 September 2022 - Following on from this week's article on early re-entry resubmissions, today we took a close look ...
Posted by Michael Wonder on 12 Sep 2022
Nomination for an early re-entry resubmission - what exactly does it mean?
12 September 2022 - We compare and contrast the submissions nominated by the PBAC in March for an early re-entry ...
Posted by Michael Wonder on 10 Sep 2022
Your money or your life? Cancer’s crushing cost
10 September 2022 - The first thing many cancer patients see when they arrive at the oncology ward is the EFTPOS ...
Posted by Michael Wonder on 09 Sep 2022
PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting
9 September 2022 - The Public Summary Documents (first time rejections and deferrals) from the May 2022 PBAC meeting are now ...
Posted by Michael Wonder on 07 Sep 2022
Cheaper scripts for millions
7 September 2022 - For the first time in its 75 year history, the maximum cost of general scripts under ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 05 Sep 2022
Collaboration arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada
5 September 2022 - The Department of Health and Aged Care has signed an international collaboration arrangement with five like minded ...
Posted by Michael Wonder on 04 Sep 2022
Australia among world's best in treating debilitating and often fatal muscle disorder
4 September - Australia has become one of the first countries in the world to fund a new, next-generation treatment ...
Posted by Michael Wonder on 02 Sep 2022
Updated agenda for the November 2022 PBAC meeting
2 September 2022 - The agenda for the November 2022 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2022
Critical kidney disease medication listed on the PBS
1 September 2022 - A life changing treatment for chronic kidney disease will be made available to thousands of Australians through ...
Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the ...
Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits ...
Posted by Michael Wonder on 31 Aug 2022
Kidney disease drug dapagliflozin added to Pharmaceutical Benefits Scheme
31 August 2022 - Lachlan Ross describes his more than a decade-long battle with kidney failure as "very long, and very ...
Posted by Michael Wonder on 31 Aug 2022
Schedule of Pharmaceutical Benefits - 1 September 2022
1 September 2022 - The September 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Aug 2022
First new kidney treatment in 20 years delays dialysis and transplant
31 August 2022 - Kidney disease is Australia’s silent killer, with nine in 10 patients unaware they have it until too ...